Review



ampk inhibitor compound c  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 98

    Structured Review

    MedChemExpress ampk inhibitor compound c
    Protective effect of rMyonectin against LPS-induced apoptosis in cardiomyocytes is mediated by <t>AMPK</t> activation. (A) Western blot analysis and semi-quantification of p-AMPK and AMPK in myocardial tissue. (B) Western blot analysis and semi-quantification of p-AMPK and AMPK in NMCMs. (C) Expression of p-AMPK and AMPK in NMCMs after CC treatment. (D) Intracellular LDH activity in NMCMs. (E) The percentage of apoptotic cells detected using flow cytometry. (F) Apoptosis was assessed using flow cytometry after double labeling with Annexin V-FITC and PI. (G) Western blot analysis and semi-quantification of cleaved caspase-3, caspase-3, Bax and Bcl-2 protein expression in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AMPK, AMP-activated protein kinase; CC, Compound C; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; PI, propidium iodide; p-, phosphorylated.
    Ampk Inhibitor Compound C, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 815 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+c/Dorsomorphin/pmc13314204-108-11-22
    Average 98 stars, based on 815 article reviews
    ampk inhibitor compound c - by Bioz Stars, 2026-09
    98/100 stars

    Images

    1) Product Images from "Recombinant myonectin ameliorates sepsis-induced cardiomyopathy by alleviating mitochondrial dysfunction via the AdipoR1/AMPK pathway"

    Article Title: Recombinant myonectin ameliorates sepsis-induced cardiomyopathy by alleviating mitochondrial dysfunction via the AdipoR1/AMPK pathway

    Journal: International Journal of Molecular Medicine

    doi: 10.3892/ijmm.2026.5900

    Protective effect of rMyonectin against LPS-induced apoptosis in cardiomyocytes is mediated by AMPK activation. (A) Western blot analysis and semi-quantification of p-AMPK and AMPK in myocardial tissue. (B) Western blot analysis and semi-quantification of p-AMPK and AMPK in NMCMs. (C) Expression of p-AMPK and AMPK in NMCMs after CC treatment. (D) Intracellular LDH activity in NMCMs. (E) The percentage of apoptotic cells detected using flow cytometry. (F) Apoptosis was assessed using flow cytometry after double labeling with Annexin V-FITC and PI. (G) Western blot analysis and semi-quantification of cleaved caspase-3, caspase-3, Bax and Bcl-2 protein expression in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AMPK, AMP-activated protein kinase; CC, Compound C; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; PI, propidium iodide; p-, phosphorylated.
    Figure Legend Snippet: Protective effect of rMyonectin against LPS-induced apoptosis in cardiomyocytes is mediated by AMPK activation. (A) Western blot analysis and semi-quantification of p-AMPK and AMPK in myocardial tissue. (B) Western blot analysis and semi-quantification of p-AMPK and AMPK in NMCMs. (C) Expression of p-AMPK and AMPK in NMCMs after CC treatment. (D) Intracellular LDH activity in NMCMs. (E) The percentage of apoptotic cells detected using flow cytometry. (F) Apoptosis was assessed using flow cytometry after double labeling with Annexin V-FITC and PI. (G) Western blot analysis and semi-quantification of cleaved caspase-3, caspase-3, Bax and Bcl-2 protein expression in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AMPK, AMP-activated protein kinase; CC, Compound C; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; PI, propidium iodide; p-, phosphorylated.

    Techniques Used: Activation Assay, Western Blot, Expressing, Activity Assay, Flow Cytometry, Labeling, Recombinant

    Protective effect of rMyonectin against LPS-induced mitochondrial dysfunction in cardiomyocytes is mediated by AMPK activation. (A) The ATP content in NMCMs. (B) Relative OCR. (C) Detection of the activities of mitochondrial respiratory chain complexes I and III. (D) Analysis of MMP using JC-1 staining. Scale bar, 50 μ m. (E) Western blot analysis and semi-quantification of PGC-1α, NRF1, TFAM, OPA1, Mfn2, p-Drp1 at Ser616, and Drp1 in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; OCR, oxygen consumption rate; MMP, mitochondrial membrane potential; PGC-1α, peroxisome proliferator-activated receptor γ co-activator-1 α; NRF1, nuclear respiratory factor 1; TFAM, mitochondrial transcription factor A; Mfn2, mitofusin 2; OPA1, optic atrophy 1; Drp1, dynamin-related protein 1; LPS, lipopolysaccharide; p-, phosphorylated.
    Figure Legend Snippet: Protective effect of rMyonectin against LPS-induced mitochondrial dysfunction in cardiomyocytes is mediated by AMPK activation. (A) The ATP content in NMCMs. (B) Relative OCR. (C) Detection of the activities of mitochondrial respiratory chain complexes I and III. (D) Analysis of MMP using JC-1 staining. Scale bar, 50 μ m. (E) Western blot analysis and semi-quantification of PGC-1α, NRF1, TFAM, OPA1, Mfn2, p-Drp1 at Ser616, and Drp1 in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; OCR, oxygen consumption rate; MMP, mitochondrial membrane potential; PGC-1α, peroxisome proliferator-activated receptor γ co-activator-1 α; NRF1, nuclear respiratory factor 1; TFAM, mitochondrial transcription factor A; Mfn2, mitofusin 2; OPA1, optic atrophy 1; Drp1, dynamin-related protein 1; LPS, lipopolysaccharide; p-, phosphorylated.

    Techniques Used: Activation Assay, Staining, Western Blot, Recombinant, Membrane

    AdipoR1 knockdown abolishes the protective effect of rMyonectin against LPS-induced apoptosis in cardiomyocytes. (A) Western blot analysis and semi-quantification of AdipoR1 in myocardial tissue. (B) Western blot analysis and semi-quantification of AdipoR1 in NMCMs. (C) Representative western blots showing the expression of AdipoR1, p-AMPK and AMPK in NMCMs following AdipoR1 knockdown. (D) Semi-quantification of AdipoR1, p-AMPK and AMPK protein levels in NMCMs following AdipoR1 knockdown. (E) Intracellular LDH activity in NMCMs. (F) The percentage of apoptotic cells detected using flow cytometry. (G) Apoptosis was assessed using flow cytometry after double labeling with Annexin V-FITC and PI. (H) Western blot analysis and semi-quantification of cleaved caspase-3, caspase-3, Bax, and Bcl-2 protein expression in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AdipoR1, adiponectin receptor 1; AMPK, AMP-activated protein kinase; LDH, lactate dehydrogenase; si, small interfering RNA; NC, negative control; siAdipoR1, siRNA targeting AdipoR1; LPS, lipopolysaccharide; p-, phosphorylated; PI, propidium iodide.
    Figure Legend Snippet: AdipoR1 knockdown abolishes the protective effect of rMyonectin against LPS-induced apoptosis in cardiomyocytes. (A) Western blot analysis and semi-quantification of AdipoR1 in myocardial tissue. (B) Western blot analysis and semi-quantification of AdipoR1 in NMCMs. (C) Representative western blots showing the expression of AdipoR1, p-AMPK and AMPK in NMCMs following AdipoR1 knockdown. (D) Semi-quantification of AdipoR1, p-AMPK and AMPK protein levels in NMCMs following AdipoR1 knockdown. (E) Intracellular LDH activity in NMCMs. (F) The percentage of apoptotic cells detected using flow cytometry. (G) Apoptosis was assessed using flow cytometry after double labeling with Annexin V-FITC and PI. (H) Western blot analysis and semi-quantification of cleaved caspase-3, caspase-3, Bax, and Bcl-2 protein expression in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AdipoR1, adiponectin receptor 1; AMPK, AMP-activated protein kinase; LDH, lactate dehydrogenase; si, small interfering RNA; NC, negative control; siAdipoR1, siRNA targeting AdipoR1; LPS, lipopolysaccharide; p-, phosphorylated; PI, propidium iodide.

    Techniques Used: Knockdown, Western Blot, Expressing, Activity Assay, Flow Cytometry, Labeling, Recombinant, Small Interfering RNA, Negative Control

    AdipoR1 knockdown abolishes the protective effect of rMyonectin against LPS-induced mitochondrial dysfunction in cardiomyocytes. (A) The ATP content in NMCMs. (B) Relative OCR. (C) Detection of the activities of mitochondrial respiratory chain complexes I and III. (D) Analysis of MMP using JC-1 staining. Scale bar, 50 μ m. (E) Western blot analysis and semi-quantification of PGC-1α, NRF1, TFAM, OPA1, Mfn2, p-Drp1 at Ser616 and Drp1 in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AdipoR1, adiponectin receptor 1; AMPK, AMP-activated protein kinase; OCR, oxygen consumption rate; MMP, mitochondrial membrane potential; PGC-1α, peroxisome proliferator-activated receptor γ co-activator-1 α; NRF1, nuclear respiratory factor 1; TFAM, mitochondrial transcription factor A; Mfn2, mitofusin 2; OPA1, optic atrophy 1; Drp1, dynamin-related protein 1; si, small interfering RNA; NC, negative control; siAdipoR1, siRNA targeting AdipoR1; LPS, lipopolysaccharide; p-, phosphorylated.
    Figure Legend Snippet: AdipoR1 knockdown abolishes the protective effect of rMyonectin against LPS-induced mitochondrial dysfunction in cardiomyocytes. (A) The ATP content in NMCMs. (B) Relative OCR. (C) Detection of the activities of mitochondrial respiratory chain complexes I and III. (D) Analysis of MMP using JC-1 staining. Scale bar, 50 μ m. (E) Western blot analysis and semi-quantification of PGC-1α, NRF1, TFAM, OPA1, Mfn2, p-Drp1 at Ser616 and Drp1 in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AdipoR1, adiponectin receptor 1; AMPK, AMP-activated protein kinase; OCR, oxygen consumption rate; MMP, mitochondrial membrane potential; PGC-1α, peroxisome proliferator-activated receptor γ co-activator-1 α; NRF1, nuclear respiratory factor 1; TFAM, mitochondrial transcription factor A; Mfn2, mitofusin 2; OPA1, optic atrophy 1; Drp1, dynamin-related protein 1; si, small interfering RNA; NC, negative control; siAdipoR1, siRNA targeting AdipoR1; LPS, lipopolysaccharide; p-, phosphorylated.

    Techniques Used: Knockdown, Staining, Western Blot, Recombinant, Membrane, Small Interfering RNA, Negative Control

    Molecular mechanism by which rMyonectin ameliorates SIC. rMyonectin ameliorates SIC by alleviating mitochondrial dysfunction and inhibiting cardiomyocyte apoptosis via activation of the AdipoR1/AMPK pathway. rMyonectin, recombinant myonectin; SIC, sepsis-induced cardiomyopathy; OMM, outer mitochondrial membranes; IMM, inner mitochondrial membranes; AdipoR1, adiponectin receptor 1; AMPK, AMP-activated protein kinase; PGC-1α, peroxisome proliferator-activated receptor γ co-activator-1 α; NRF1, nuclear respiratory factor 1; TFAM, mitochondrial transcription factor A; Mfn2, mitofusin 2; OPA1, optic atrophy 1; Drp1, dynamin-related protein 1; I, mitochondrial respiratory chain complex I; III, mitochondrial respiratory chain complex III; p-, phosphorylated.
    Figure Legend Snippet: Molecular mechanism by which rMyonectin ameliorates SIC. rMyonectin ameliorates SIC by alleviating mitochondrial dysfunction and inhibiting cardiomyocyte apoptosis via activation of the AdipoR1/AMPK pathway. rMyonectin, recombinant myonectin; SIC, sepsis-induced cardiomyopathy; OMM, outer mitochondrial membranes; IMM, inner mitochondrial membranes; AdipoR1, adiponectin receptor 1; AMPK, AMP-activated protein kinase; PGC-1α, peroxisome proliferator-activated receptor γ co-activator-1 α; NRF1, nuclear respiratory factor 1; TFAM, mitochondrial transcription factor A; Mfn2, mitofusin 2; OPA1, optic atrophy 1; Drp1, dynamin-related protein 1; I, mitochondrial respiratory chain complex I; III, mitochondrial respiratory chain complex III; p-, phosphorylated.

    Techniques Used: Activation Assay, Recombinant

    Related Articles

    Inhibition:

    Article Title: Molecular mechanisms of autophagy disorder in diabetic neuropathy: Focusing on signaling pathways and regulation of lipid metabolism
    Article Snippet: Autophagy modulation was achieved using rapamycin (100 nM, MCE, Cat#HY-10219) or 3-methyladenine (5 mM, Sigma, Cat#M9281). .. For signaling pathway investigation, cells were pre-treated with compound C (10 μM, MCE, CatHY-13418A) or MK-2206 (5 μM, MCE, Cat#HY-10358) for AMPK and Akt inhibition, respectively, 2 hours before high glucose treatment. .. Gene silencing was performed using siRNA transfection with Lipofectamine RNAiMAX (Invitrogen, Cat#13778150), with effectiveness verified through RT-qPCR and Western blot analysis.

    Article Title: Octanoic acid alleviates intestinal oxidative stress via the AMPK/PGC-1α pathway in large yellow croaker larvae
    Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article.

    In Vitro:

    Article Title: <scp>SRM</scp> ‐Mediated Spermidine Synthesis Links Lipid Overload With <scp>AMPK</scp> Pathway to Regulate Hepatic Insulin Signaling and Gluconeogenesis
    Article Snippet: .. To simulate dietary HFD conditions in vitro, hepatocytes were exposed to 200 μM palmitic acid (PA; Sigma- Merck, USA) conjugated to fatty acid- free bovine serum albumin (BSA) for 12 h. To investigate the mechanism by which SRM regulated the insulin signaling pathway, 150, 300, or 450 μM SPD (Med Chem Express, #HY- B1776) was added to the culture medium of hepatocytes for 12 h in the presence or absence of PA. To inhibit XBP1, 300 nM toyocamycin (Med Chem Express, #HY103248) was added to the culture medium of hepatocytes for 12 h in the presence of PA. To inhibit SRM, 250 μM, 500 μM, or 1000 μM trans- 4- methylcyclohexylamine (MCHA, Merck, #177466) was added to the culture medium of hepatocytes for 12 h in the presence or absence of PA. To inhibit AMPK, 10 μM Compound C (Med Chem Express, # HY- 13418A) was added to the culture medium of hepatocytes for 12 h in the presence of PA. ..

    Targeted Proteomics:

    Article Title: <scp>SRM</scp> ‐Mediated Spermidine Synthesis Links Lipid Overload With <scp>AMPK</scp> Pathway to Regulate Hepatic Insulin Signaling and Gluconeogenesis
    Article Snippet: .. To simulate dietary HFD conditions in vitro, hepatocytes were exposed to 200 μM palmitic acid (PA; Sigma- Merck, USA) conjugated to fatty acid- free bovine serum albumin (BSA) for 12 h. To investigate the mechanism by which SRM regulated the insulin signaling pathway, 150, 300, or 450 μM SPD (Med Chem Express, #HY- B1776) was added to the culture medium of hepatocytes for 12 h in the presence or absence of PA. To inhibit XBP1, 300 nM toyocamycin (Med Chem Express, #HY103248) was added to the culture medium of hepatocytes for 12 h in the presence of PA. To inhibit SRM, 250 μM, 500 μM, or 1000 μM trans- 4- methylcyclohexylamine (MCHA, Merck, #177466) was added to the culture medium of hepatocytes for 12 h in the presence or absence of PA. To inhibit AMPK, 10 μM Compound C (Med Chem Express, # HY- 13418A) was added to the culture medium of hepatocytes for 12 h in the presence of PA. ..

    Staining:

    Article Title: Gastrodin alleviates cardiomyocyte senescence by regulating autophagy through the AMPK/mTOR/4EBP1 pathway
    Article Snippet: The rat H9c2 cardiomyocyte cell line was purchased from procell life science & technology co., ltd (Batch No. CL-0089) and was used for subsequent experiments after three passages. .. Doxorubicin hydrochloride (Doxorubicin hydrochloride, MCE, China, HY-15142), gastrodin (Gastrodin, MCE, China, HY-N0115), 3-methyladenine (3-Methyladenine, MCE, China, HY-19312), Compound C (Dorsomorphin dihydrochloride, MCE, China, HY-13418), dimethyl sulfoxide (DMSO, MCE, China, HY-Y0320C), high-glucose DMEM medium (Procell, China, PM150210), penicillin–streptomycin solution (100×) (Beyotime, China, C0222), fetal bovine serum (FBS, PAN), trypsin digestion solution (0.25% trypsin) (Beyotime, China, C0201), 1× PBS buffer (pH 7.2–7.4) (Solarbio, China, P1020), senescence β-galactosidase staining kit (Beyotime, China, C0602), Triton X-100 (Solarbio, China, IT9100), bovine serum albumin BSA-V (Solarbio, China, A8020), AF488-conjugated goat anti-rabbit IgG (Beyotime, China, A0423), skim milk powder (Solarbio, China, LP0033B), serum-free cell freezing medium (New Cell & Molecular Biotech, China, C40100 ), SDS-PAGE protein loading buffer (5×) (Beyotime, China, P0015L), 20× TBST buffer (Solarbio, China, T1082), Omni-EasyTM one-step stain-free PAGE gel rapid preparation kit (Yeasen, China, PG221, PG222, PG223), P53 (Proteintech, China, 10442-1-AP), P21 (Proteintech, China, 28248-1-AP), P16 (Proteintech, China, 28416-1-AP), LC3-II/I (Affinity, China, AF5402), p62 (Affinity, China, AF5384), Beclin-1 (Affinity, China, AF5128), Phospho-AMPK (Affinity, China, AF3423), AMPK (Affinity, China, AF6423), Phospho-mTOR (Affinity, China, AF3308), mTOR (Affinity, China, AF6308), Phospho-4EBP1 (Affinity, China, AF3830), and 4EBP1 (Affinity, China, AF6432). .. Chemiluminescence imaging system (Qinxiang, China, Chemiscope 6200), vertical electrophoresis system (Bio-Rad, China, Mini-PROTEAN), fluorescence microscope (EVOS, United States, FL Auto2), inverted fluorescence microscope (Nikon, Japan, ECLIPSE Ti2-U), and flow cytometer (BD, United States, FACSCanto II).

    SDS Page:

    Article Title: Gastrodin alleviates cardiomyocyte senescence by regulating autophagy through the AMPK/mTOR/4EBP1 pathway
    Article Snippet: The rat H9c2 cardiomyocyte cell line was purchased from procell life science & technology co., ltd (Batch No. CL-0089) and was used for subsequent experiments after three passages. .. Doxorubicin hydrochloride (Doxorubicin hydrochloride, MCE, China, HY-15142), gastrodin (Gastrodin, MCE, China, HY-N0115), 3-methyladenine (3-Methyladenine, MCE, China, HY-19312), Compound C (Dorsomorphin dihydrochloride, MCE, China, HY-13418), dimethyl sulfoxide (DMSO, MCE, China, HY-Y0320C), high-glucose DMEM medium (Procell, China, PM150210), penicillin–streptomycin solution (100×) (Beyotime, China, C0222), fetal bovine serum (FBS, PAN), trypsin digestion solution (0.25% trypsin) (Beyotime, China, C0201), 1× PBS buffer (pH 7.2–7.4) (Solarbio, China, P1020), senescence β-galactosidase staining kit (Beyotime, China, C0602), Triton X-100 (Solarbio, China, IT9100), bovine serum albumin BSA-V (Solarbio, China, A8020), AF488-conjugated goat anti-rabbit IgG (Beyotime, China, A0423), skim milk powder (Solarbio, China, LP0033B), serum-free cell freezing medium (New Cell & Molecular Biotech, China, C40100 ), SDS-PAGE protein loading buffer (5×) (Beyotime, China, P0015L), 20× TBST buffer (Solarbio, China, T1082), Omni-EasyTM one-step stain-free PAGE gel rapid preparation kit (Yeasen, China, PG221, PG222, PG223), P53 (Proteintech, China, 10442-1-AP), P21 (Proteintech, China, 28248-1-AP), P16 (Proteintech, China, 28416-1-AP), LC3-II/I (Affinity, China, AF5402), p62 (Affinity, China, AF5384), Beclin-1 (Affinity, China, AF5128), Phospho-AMPK (Affinity, China, AF3423), AMPK (Affinity, China, AF6423), Phospho-mTOR (Affinity, China, AF3308), mTOR (Affinity, China, AF6308), Phospho-4EBP1 (Affinity, China, AF3830), and 4EBP1 (Affinity, China, AF6432). .. Chemiluminescence imaging system (Qinxiang, China, Chemiscope 6200), vertical electrophoresis system (Bio-Rad, China, Mini-PROTEAN), fluorescence microscope (EVOS, United States, FL Auto2), inverted fluorescence microscope (Nikon, Japan, ECLIPSE Ti2-U), and flow cytometer (BD, United States, FACSCanto II).

    Polyacrylamide Gel Electrophoresis:

    Article Title: Gastrodin alleviates cardiomyocyte senescence by regulating autophagy through the AMPK/mTOR/4EBP1 pathway
    Article Snippet: The rat H9c2 cardiomyocyte cell line was purchased from procell life science & technology co., ltd (Batch No. CL-0089) and was used for subsequent experiments after three passages. .. Doxorubicin hydrochloride (Doxorubicin hydrochloride, MCE, China, HY-15142), gastrodin (Gastrodin, MCE, China, HY-N0115), 3-methyladenine (3-Methyladenine, MCE, China, HY-19312), Compound C (Dorsomorphin dihydrochloride, MCE, China, HY-13418), dimethyl sulfoxide (DMSO, MCE, China, HY-Y0320C), high-glucose DMEM medium (Procell, China, PM150210), penicillin–streptomycin solution (100×) (Beyotime, China, C0222), fetal bovine serum (FBS, PAN), trypsin digestion solution (0.25% trypsin) (Beyotime, China, C0201), 1× PBS buffer (pH 7.2–7.4) (Solarbio, China, P1020), senescence β-galactosidase staining kit (Beyotime, China, C0602), Triton X-100 (Solarbio, China, IT9100), bovine serum albumin BSA-V (Solarbio, China, A8020), AF488-conjugated goat anti-rabbit IgG (Beyotime, China, A0423), skim milk powder (Solarbio, China, LP0033B), serum-free cell freezing medium (New Cell & Molecular Biotech, China, C40100 ), SDS-PAGE protein loading buffer (5×) (Beyotime, China, P0015L), 20× TBST buffer (Solarbio, China, T1082), Omni-EasyTM one-step stain-free PAGE gel rapid preparation kit (Yeasen, China, PG221, PG222, PG223), P53 (Proteintech, China, 10442-1-AP), P21 (Proteintech, China, 28248-1-AP), P16 (Proteintech, China, 28416-1-AP), LC3-II/I (Affinity, China, AF5402), p62 (Affinity, China, AF5384), Beclin-1 (Affinity, China, AF5128), Phospho-AMPK (Affinity, China, AF3423), AMPK (Affinity, China, AF6423), Phospho-mTOR (Affinity, China, AF3308), mTOR (Affinity, China, AF6308), Phospho-4EBP1 (Affinity, China, AF3830), and 4EBP1 (Affinity, China, AF6432). .. Chemiluminescence imaging system (Qinxiang, China, Chemiscope 6200), vertical electrophoresis system (Bio-Rad, China, Mini-PROTEAN), fluorescence microscope (EVOS, United States, FL Auto2), inverted fluorescence microscope (Nikon, Japan, ECLIPSE Ti2-U), and flow cytometer (BD, United States, FACSCanto II).

    other:

    Article Title: PPP2R5B regulates ANPEP expression and TGEV entry via dephosphorylation of HSF1 at Ser304/Ser308
    Article Snippet: Cells were treated with specific inhibitors, including LB-100 (MCE, HY-15431), Compound C (MCE, HY-13418A), AICAR (MCE, HY-13417), and Capivasertib (MCE, HY-15431), prepared as stock solutions and diluted to working concentrations prior to use.

    Article Title: The Zuo Jin Wan Formula Reverses Cisplatin Resistance in Gastric Cancer by Inhibiting the Mitochondrial Translocation of Dynamin‐Related Protein 1 and Its Mediated Mitochondrial Fission and Mitophagy
    Article Snippet: Cyclosporine A (catalog no. HY‐B0579), metformin (Met; catalog no. HY‐B0627), and compound C (catalog no. HY‐13418A) were purchased from MedChemExpress (Monmouth Junction, NJ).

    Pyrolysis Gas Chromatography:

    Article Title: Octanoic acid alleviates intestinal oxidative stress via the AMPK/PGC-1α pathway in large yellow croaker larvae
    Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article.

    Transfection:

    Article Title: Octanoic acid alleviates intestinal oxidative stress via the AMPK/PGC-1α pathway in large yellow croaker larvae
    Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article.



    Similar Products

    98
    MedChemExpress ampk inhibitor compound c
    Protective effect of rMyonectin against LPS-induced apoptosis in cardiomyocytes is mediated by <t>AMPK</t> activation. (A) Western blot analysis and semi-quantification of p-AMPK and AMPK in myocardial tissue. (B) Western blot analysis and semi-quantification of p-AMPK and AMPK in NMCMs. (C) Expression of p-AMPK and AMPK in NMCMs after CC treatment. (D) Intracellular LDH activity in NMCMs. (E) The percentage of apoptotic cells detected using flow cytometry. (F) Apoptosis was assessed using flow cytometry after double labeling with Annexin V-FITC and PI. (G) Western blot analysis and semi-quantification of cleaved caspase-3, caspase-3, Bax and Bcl-2 protein expression in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AMPK, AMP-activated protein kinase; CC, Compound C; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; PI, propidium iodide; p-, phosphorylated.
    Ampk Inhibitor Compound C, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+c/Dorsomorphin/pmc13314204-108-11-22
    Average 98 stars, based on 1 article reviews
    ampk inhibitor compound c - by Bioz Stars, 2026-09
    98/100 stars
      Buy from Supplier

    98
    MedChemExpress compound c
    Protective effect of rMyonectin against LPS-induced apoptosis in cardiomyocytes is mediated by <t>AMPK</t> activation. (A) Western blot analysis and semi-quantification of p-AMPK and AMPK in myocardial tissue. (B) Western blot analysis and semi-quantification of p-AMPK and AMPK in NMCMs. (C) Expression of p-AMPK and AMPK in NMCMs after CC treatment. (D) Intracellular LDH activity in NMCMs. (E) The percentage of apoptotic cells detected using flow cytometry. (F) Apoptosis was assessed using flow cytometry after double labeling with Annexin V-FITC and PI. (G) Western blot analysis and semi-quantification of cleaved caspase-3, caspase-3, Bax and Bcl-2 protein expression in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AMPK, AMP-activated protein kinase; CC, Compound C; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; PI, propidium iodide; p-, phosphorylated.
    Compound C, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+c/Dorsomorphin/pmc13417473-45-11-19
    Average 98 stars, based on 1 article reviews
    compound c - by Bioz Stars, 2026-09
    98/100 stars
      Buy from Supplier

    86
    Sakura Finetek cutting temperature o c t compound
    Protective effect of rMyonectin against LPS-induced apoptosis in cardiomyocytes is mediated by <t>AMPK</t> activation. (A) Western blot analysis and semi-quantification of p-AMPK and AMPK in myocardial tissue. (B) Western blot analysis and semi-quantification of p-AMPK and AMPK in NMCMs. (C) Expression of p-AMPK and AMPK in NMCMs after CC treatment. (D) Intracellular LDH activity in NMCMs. (E) The percentage of apoptotic cells detected using flow cytometry. (F) Apoptosis was assessed using flow cytometry after double labeling with Annexin V-FITC and PI. (G) Western blot analysis and semi-quantification of cleaved caspase-3, caspase-3, Bax and Bcl-2 protein expression in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AMPK, AMP-activated protein kinase; CC, Compound C; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; PI, propidium iodide; p-, phosphorylated.
    Cutting Temperature O C T Compound, supplied by Sakura Finetek, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+c/compound+cutting+temperature/pmc13263628-276-29-33
    Average 86 stars, based on 1 article reviews
    cutting temperature o c t compound - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    96
    MedChemExpress compound c dorsomorphin
    Protective effect of rMyonectin against LPS-induced apoptosis in cardiomyocytes is mediated by <t>AMPK</t> activation. (A) Western blot analysis and semi-quantification of p-AMPK and AMPK in myocardial tissue. (B) Western blot analysis and semi-quantification of p-AMPK and AMPK in NMCMs. (C) Expression of p-AMPK and AMPK in NMCMs after CC treatment. (D) Intracellular LDH activity in NMCMs. (E) The percentage of apoptotic cells detected using flow cytometry. (F) Apoptosis was assessed using flow cytometry after double labeling with Annexin V-FITC and PI. (G) Western blot analysis and semi-quantification of cleaved caspase-3, caspase-3, Bax and Bcl-2 protein expression in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AMPK, AMP-activated protein kinase; CC, Compound C; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; PI, propidium iodide; p-, phosphorylated.
    Compound C Dorsomorphin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+c/Dorsomorphin+dihydrochloride/pm42364552-83-20-32
    Average 96 stars, based on 1 article reviews
    compound c dorsomorphin - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    86
    Sakura Finetek tissue tek o c t compound
    Protective effect of rMyonectin against LPS-induced apoptosis in cardiomyocytes is mediated by <t>AMPK</t> activation. (A) Western blot analysis and semi-quantification of p-AMPK and AMPK in myocardial tissue. (B) Western blot analysis and semi-quantification of p-AMPK and AMPK in NMCMs. (C) Expression of p-AMPK and AMPK in NMCMs after CC treatment. (D) Intracellular LDH activity in NMCMs. (E) The percentage of apoptotic cells detected using flow cytometry. (F) Apoptosis was assessed using flow cytometry after double labeling with Annexin V-FITC and PI. (G) Western blot analysis and semi-quantification of cleaved caspase-3, caspase-3, Bax and Bcl-2 protein expression in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AMPK, AMP-activated protein kinase; CC, Compound C; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; PI, propidium iodide; p-, phosphorylated.
    Tissue Tek O C T Compound, supplied by Sakura Finetek, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+c/compound+oct/pm42310735-117-8-11
    Average 86 stars, based on 1 article reviews
    tissue tek o c t compound - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    86
    Scigen Inc o c t compound cryostat embedding medium
    Protective effect of rMyonectin against LPS-induced apoptosis in cardiomyocytes is mediated by <t>AMPK</t> activation. (A) Western blot analysis and semi-quantification of p-AMPK and AMPK in myocardial tissue. (B) Western blot analysis and semi-quantification of p-AMPK and AMPK in NMCMs. (C) Expression of p-AMPK and AMPK in NMCMs after CC treatment. (D) Intracellular LDH activity in NMCMs. (E) The percentage of apoptotic cells detected using flow cytometry. (F) Apoptosis was assessed using flow cytometry after double labeling with Annexin V-FITC and PI. (G) Western blot analysis and semi-quantification of cleaved caspase-3, caspase-3, Bax and Bcl-2 protein expression in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AMPK, AMP-activated protein kinase; CC, Compound C; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; PI, propidium iodide; p-, phosphorylated.
    O C T Compound Cryostat Embedding Medium, supplied by Scigen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+c/c+compound+cryostat+embedding+medium+o+t/pmc13196551-27-0-6
    Average 86 stars, based on 1 article reviews
    o c t compound cryostat embedding medium - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    Image Search Results


    Protective effect of rMyonectin against LPS-induced apoptosis in cardiomyocytes is mediated by AMPK activation. (A) Western blot analysis and semi-quantification of p-AMPK and AMPK in myocardial tissue. (B) Western blot analysis and semi-quantification of p-AMPK and AMPK in NMCMs. (C) Expression of p-AMPK and AMPK in NMCMs after CC treatment. (D) Intracellular LDH activity in NMCMs. (E) The percentage of apoptotic cells detected using flow cytometry. (F) Apoptosis was assessed using flow cytometry after double labeling with Annexin V-FITC and PI. (G) Western blot analysis and semi-quantification of cleaved caspase-3, caspase-3, Bax and Bcl-2 protein expression in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AMPK, AMP-activated protein kinase; CC, Compound C; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; PI, propidium iodide; p-, phosphorylated.

    Journal: International Journal of Molecular Medicine

    Article Title: Recombinant myonectin ameliorates sepsis-induced cardiomyopathy by alleviating mitochondrial dysfunction via the AdipoR1/AMPK pathway

    doi: 10.3892/ijmm.2026.5900

    Figure Lengend Snippet: Protective effect of rMyonectin against LPS-induced apoptosis in cardiomyocytes is mediated by AMPK activation. (A) Western blot analysis and semi-quantification of p-AMPK and AMPK in myocardial tissue. (B) Western blot analysis and semi-quantification of p-AMPK and AMPK in NMCMs. (C) Expression of p-AMPK and AMPK in NMCMs after CC treatment. (D) Intracellular LDH activity in NMCMs. (E) The percentage of apoptotic cells detected using flow cytometry. (F) Apoptosis was assessed using flow cytometry after double labeling with Annexin V-FITC and PI. (G) Western blot analysis and semi-quantification of cleaved caspase-3, caspase-3, Bax and Bcl-2 protein expression in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AMPK, AMP-activated protein kinase; CC, Compound C; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; PI, propidium iodide; p-, phosphorylated.

    Article Snippet: NMCMs were pretreated for 2 h with rMyonectin or with the AMPK inhibitor Compound C (CC; 10 μ M; cat. no. HY-13418A; MedChemExpress) ( , ), followed by stimulation with 10 μ g/ml LPS for 24 h ( ).

    Techniques: Activation Assay, Western Blot, Expressing, Activity Assay, Flow Cytometry, Labeling, Recombinant

    Protective effect of rMyonectin against LPS-induced mitochondrial dysfunction in cardiomyocytes is mediated by AMPK activation. (A) The ATP content in NMCMs. (B) Relative OCR. (C) Detection of the activities of mitochondrial respiratory chain complexes I and III. (D) Analysis of MMP using JC-1 staining. Scale bar, 50 μ m. (E) Western blot analysis and semi-quantification of PGC-1α, NRF1, TFAM, OPA1, Mfn2, p-Drp1 at Ser616, and Drp1 in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; OCR, oxygen consumption rate; MMP, mitochondrial membrane potential; PGC-1α, peroxisome proliferator-activated receptor γ co-activator-1 α; NRF1, nuclear respiratory factor 1; TFAM, mitochondrial transcription factor A; Mfn2, mitofusin 2; OPA1, optic atrophy 1; Drp1, dynamin-related protein 1; LPS, lipopolysaccharide; p-, phosphorylated.

    Journal: International Journal of Molecular Medicine

    Article Title: Recombinant myonectin ameliorates sepsis-induced cardiomyopathy by alleviating mitochondrial dysfunction via the AdipoR1/AMPK pathway

    doi: 10.3892/ijmm.2026.5900

    Figure Lengend Snippet: Protective effect of rMyonectin against LPS-induced mitochondrial dysfunction in cardiomyocytes is mediated by AMPK activation. (A) The ATP content in NMCMs. (B) Relative OCR. (C) Detection of the activities of mitochondrial respiratory chain complexes I and III. (D) Analysis of MMP using JC-1 staining. Scale bar, 50 μ m. (E) Western blot analysis and semi-quantification of PGC-1α, NRF1, TFAM, OPA1, Mfn2, p-Drp1 at Ser616, and Drp1 in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; OCR, oxygen consumption rate; MMP, mitochondrial membrane potential; PGC-1α, peroxisome proliferator-activated receptor γ co-activator-1 α; NRF1, nuclear respiratory factor 1; TFAM, mitochondrial transcription factor A; Mfn2, mitofusin 2; OPA1, optic atrophy 1; Drp1, dynamin-related protein 1; LPS, lipopolysaccharide; p-, phosphorylated.

    Article Snippet: NMCMs were pretreated for 2 h with rMyonectin or with the AMPK inhibitor Compound C (CC; 10 μ M; cat. no. HY-13418A; MedChemExpress) ( , ), followed by stimulation with 10 μ g/ml LPS for 24 h ( ).

    Techniques: Activation Assay, Staining, Western Blot, Recombinant, Membrane

    AdipoR1 knockdown abolishes the protective effect of rMyonectin against LPS-induced apoptosis in cardiomyocytes. (A) Western blot analysis and semi-quantification of AdipoR1 in myocardial tissue. (B) Western blot analysis and semi-quantification of AdipoR1 in NMCMs. (C) Representative western blots showing the expression of AdipoR1, p-AMPK and AMPK in NMCMs following AdipoR1 knockdown. (D) Semi-quantification of AdipoR1, p-AMPK and AMPK protein levels in NMCMs following AdipoR1 knockdown. (E) Intracellular LDH activity in NMCMs. (F) The percentage of apoptotic cells detected using flow cytometry. (G) Apoptosis was assessed using flow cytometry after double labeling with Annexin V-FITC and PI. (H) Western blot analysis and semi-quantification of cleaved caspase-3, caspase-3, Bax, and Bcl-2 protein expression in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AdipoR1, adiponectin receptor 1; AMPK, AMP-activated protein kinase; LDH, lactate dehydrogenase; si, small interfering RNA; NC, negative control; siAdipoR1, siRNA targeting AdipoR1; LPS, lipopolysaccharide; p-, phosphorylated; PI, propidium iodide.

    Journal: International Journal of Molecular Medicine

    Article Title: Recombinant myonectin ameliorates sepsis-induced cardiomyopathy by alleviating mitochondrial dysfunction via the AdipoR1/AMPK pathway

    doi: 10.3892/ijmm.2026.5900

    Figure Lengend Snippet: AdipoR1 knockdown abolishes the protective effect of rMyonectin against LPS-induced apoptosis in cardiomyocytes. (A) Western blot analysis and semi-quantification of AdipoR1 in myocardial tissue. (B) Western blot analysis and semi-quantification of AdipoR1 in NMCMs. (C) Representative western blots showing the expression of AdipoR1, p-AMPK and AMPK in NMCMs following AdipoR1 knockdown. (D) Semi-quantification of AdipoR1, p-AMPK and AMPK protein levels in NMCMs following AdipoR1 knockdown. (E) Intracellular LDH activity in NMCMs. (F) The percentage of apoptotic cells detected using flow cytometry. (G) Apoptosis was assessed using flow cytometry after double labeling with Annexin V-FITC and PI. (H) Western blot analysis and semi-quantification of cleaved caspase-3, caspase-3, Bax, and Bcl-2 protein expression in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AdipoR1, adiponectin receptor 1; AMPK, AMP-activated protein kinase; LDH, lactate dehydrogenase; si, small interfering RNA; NC, negative control; siAdipoR1, siRNA targeting AdipoR1; LPS, lipopolysaccharide; p-, phosphorylated; PI, propidium iodide.

    Article Snippet: NMCMs were pretreated for 2 h with rMyonectin or with the AMPK inhibitor Compound C (CC; 10 μ M; cat. no. HY-13418A; MedChemExpress) ( , ), followed by stimulation with 10 μ g/ml LPS for 24 h ( ).

    Techniques: Knockdown, Western Blot, Expressing, Activity Assay, Flow Cytometry, Labeling, Recombinant, Small Interfering RNA, Negative Control

    AdipoR1 knockdown abolishes the protective effect of rMyonectin against LPS-induced mitochondrial dysfunction in cardiomyocytes. (A) The ATP content in NMCMs. (B) Relative OCR. (C) Detection of the activities of mitochondrial respiratory chain complexes I and III. (D) Analysis of MMP using JC-1 staining. Scale bar, 50 μ m. (E) Western blot analysis and semi-quantification of PGC-1α, NRF1, TFAM, OPA1, Mfn2, p-Drp1 at Ser616 and Drp1 in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AdipoR1, adiponectin receptor 1; AMPK, AMP-activated protein kinase; OCR, oxygen consumption rate; MMP, mitochondrial membrane potential; PGC-1α, peroxisome proliferator-activated receptor γ co-activator-1 α; NRF1, nuclear respiratory factor 1; TFAM, mitochondrial transcription factor A; Mfn2, mitofusin 2; OPA1, optic atrophy 1; Drp1, dynamin-related protein 1; si, small interfering RNA; NC, negative control; siAdipoR1, siRNA targeting AdipoR1; LPS, lipopolysaccharide; p-, phosphorylated.

    Journal: International Journal of Molecular Medicine

    Article Title: Recombinant myonectin ameliorates sepsis-induced cardiomyopathy by alleviating mitochondrial dysfunction via the AdipoR1/AMPK pathway

    doi: 10.3892/ijmm.2026.5900

    Figure Lengend Snippet: AdipoR1 knockdown abolishes the protective effect of rMyonectin against LPS-induced mitochondrial dysfunction in cardiomyocytes. (A) The ATP content in NMCMs. (B) Relative OCR. (C) Detection of the activities of mitochondrial respiratory chain complexes I and III. (D) Analysis of MMP using JC-1 staining. Scale bar, 50 μ m. (E) Western blot analysis and semi-quantification of PGC-1α, NRF1, TFAM, OPA1, Mfn2, p-Drp1 at Ser616 and Drp1 in NMCMs. The data are presented as mean±SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. rMyonectin, recombinant myonectin; NMCMs, neonatal mouse cardiomyocytes; AdipoR1, adiponectin receptor 1; AMPK, AMP-activated protein kinase; OCR, oxygen consumption rate; MMP, mitochondrial membrane potential; PGC-1α, peroxisome proliferator-activated receptor γ co-activator-1 α; NRF1, nuclear respiratory factor 1; TFAM, mitochondrial transcription factor A; Mfn2, mitofusin 2; OPA1, optic atrophy 1; Drp1, dynamin-related protein 1; si, small interfering RNA; NC, negative control; siAdipoR1, siRNA targeting AdipoR1; LPS, lipopolysaccharide; p-, phosphorylated.

    Article Snippet: NMCMs were pretreated for 2 h with rMyonectin or with the AMPK inhibitor Compound C (CC; 10 μ M; cat. no. HY-13418A; MedChemExpress) ( , ), followed by stimulation with 10 μ g/ml LPS for 24 h ( ).

    Techniques: Knockdown, Staining, Western Blot, Recombinant, Membrane, Small Interfering RNA, Negative Control

    Molecular mechanism by which rMyonectin ameliorates SIC. rMyonectin ameliorates SIC by alleviating mitochondrial dysfunction and inhibiting cardiomyocyte apoptosis via activation of the AdipoR1/AMPK pathway. rMyonectin, recombinant myonectin; SIC, sepsis-induced cardiomyopathy; OMM, outer mitochondrial membranes; IMM, inner mitochondrial membranes; AdipoR1, adiponectin receptor 1; AMPK, AMP-activated protein kinase; PGC-1α, peroxisome proliferator-activated receptor γ co-activator-1 α; NRF1, nuclear respiratory factor 1; TFAM, mitochondrial transcription factor A; Mfn2, mitofusin 2; OPA1, optic atrophy 1; Drp1, dynamin-related protein 1; I, mitochondrial respiratory chain complex I; III, mitochondrial respiratory chain complex III; p-, phosphorylated.

    Journal: International Journal of Molecular Medicine

    Article Title: Recombinant myonectin ameliorates sepsis-induced cardiomyopathy by alleviating mitochondrial dysfunction via the AdipoR1/AMPK pathway

    doi: 10.3892/ijmm.2026.5900

    Figure Lengend Snippet: Molecular mechanism by which rMyonectin ameliorates SIC. rMyonectin ameliorates SIC by alleviating mitochondrial dysfunction and inhibiting cardiomyocyte apoptosis via activation of the AdipoR1/AMPK pathway. rMyonectin, recombinant myonectin; SIC, sepsis-induced cardiomyopathy; OMM, outer mitochondrial membranes; IMM, inner mitochondrial membranes; AdipoR1, adiponectin receptor 1; AMPK, AMP-activated protein kinase; PGC-1α, peroxisome proliferator-activated receptor γ co-activator-1 α; NRF1, nuclear respiratory factor 1; TFAM, mitochondrial transcription factor A; Mfn2, mitofusin 2; OPA1, optic atrophy 1; Drp1, dynamin-related protein 1; I, mitochondrial respiratory chain complex I; III, mitochondrial respiratory chain complex III; p-, phosphorylated.

    Article Snippet: NMCMs were pretreated for 2 h with rMyonectin or with the AMPK inhibitor Compound C (CC; 10 μ M; cat. no. HY-13418A; MedChemExpress) ( , ), followed by stimulation with 10 μ g/ml LPS for 24 h ( ).

    Techniques: Activation Assay, Recombinant